Valuation: Avalo Therapeutics, Inc.

Market Cap 372M 332M 307M 278M 520M 35.28B 528M 3.69B 1.46B 18.48B 1.39B 1.37B 58.28B P/E 2026 *
-2.44x
P/E 2027 * -2.52x
Enterprise Value -52.34M -46.74M -43.18M -39.13M -73.21M -4.97B -74.42M -520M -206M -2.6B -196M -192M -8.21B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.31%
Yield 2026 *
0.16%
Yield 2027 * 0.01%
1 day-6.98%
1 week-38.51%
Current month-54.79%
1 month-55.92%
3 months-62.42%
6 months-50.22%
Current year-61.84%
1 week 6.53
Extreme 6.53
13.18
1 month 6.53
Extreme 6.53
15.99
Current year 6.53
Extreme 6.53
24.27
1 year 6.53
Extreme 6.53
24.27
3 years 3.39
Extreme 3.39
34.46
5 years 3.39
Extreme 3.39
7,055.95
10 years 3.39
Extreme 3.39
22,031.54
Manager TitleAgeSince
Chief Executive Officer 72 2022-02-13
Director of Finance/CFO 42 2022-02-13
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 72 2022-08-07
Director/Board Member 78 2020-10-11
Director/Board Member 55 2024-03-27
Date Insider Type Main position Quantity % Market Cap. Importance
9/30/26 Free

Director

1,322 0.0025%
9/30/26 Free

Director

1,109 0.0021%
9/30/26 Free

Director

1,352 0.0025%
Change 5-day change 1-year change 3-year change Capi.($)
-6.98%-38.51%-60.56%-72.94% 372M
+2.41%+0.29%+39.41%+72.14% 64.69B
-0.15%+7.50%+11.42%+71.27% 54.78B
+0.57%+4.60%+7.71%+90.93% 53.49B
+0.37%+4.67%+26.68%+49.64% 45.98B
-1.21%+2.32%+21.50%+118.33% 42.94B
-0.37%+5.07%+243.23%+789.58% 40.08B
+0.05%+0.21%+18.06%+48.50% 33.52B
+1.19%-4.98%+26.31%-0.76% 23.97B
-0.38%+5.68%+38.39%+28.35% 23.67B
Average -0.45%-1.68%+37.21%+119.51% 38.35B
Weighted average by Cap. +0.38%+2.69%+45.91%+142.63%

Financials

2026 *2027 *
Net sales - -
Net income -111M -99.31M -91.74M -83.14M -156M -10.56B -158M -1.1B -437M -5.53B -417M -408M -17.44B -133M -118M -109M -99.06M -185M -12.58B -188M -1.32B -521M -6.59B -497M -487M -20.78B
Net Debt -424M -379M -350M -317M -593M -40.25B -603M -4.21B -1.67B -21.09B -1.59B -1.56B -66.49B -306M -273M -252M -228M -427M -29.01B -434M -3.03B -1.2B -15.2B -1.15B -1.12B -47.91B
Projected Income Statement - Annual - Avalo Therapeutics, Inc.
Logo Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).
Employees
33
Date Price Change Volume
26-10-23 US$6.930 -6.98% 4,551,356
26-10-22 US$7.450 -39.23% 26,189,975
26-10-21 US$12.26 -0.81% 930,224
26-10-20 US$12.36 +6.64% 1,869,562
26-10-19 US$11.59 +2.84% 2,221,902
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Avalo Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
6.930USD
Average target price
38.50USD
Spread / Average Target
+455.56%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Avalo Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. AVTX Stock